$ATOS News

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stock

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Atossa plans shareholder stake in potential PRV proceeds

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

ATOS: Multiple Catalysts Converge in 2H26

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Presents Mechanism-Driven (Z)-Endoxifen Data In McCune-Albright Syndrome At 2026 AACR Special Conference In Cancer Research

Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

ATOS: Raises up to $16.5 Million in Registered Direct Offering

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Enters Securities Purchase Agreement With Institutional Investors For 1,363,638 Shares